Reflecting on RSV's Greatest Accomplishments of 2025
Dear Friends and Supporters,
At Roivant Social Ventures (RSV) our vision is a world where every person is born with the right and ability to access medicine and medical care, regardless of their geographic location, wealth, or insurance status. In striving for this goal, we have built out an innovative philanthropic model and programmatic work to increase access to therapeutics for underserved people and to embed these principles throughout the biotechnology and healthcare industries.
I am proud to share that in 2025 RSV:
Expanded our Global Access Fellowship Program, which provides fellowship grants to talented PharmD students that allow their unique skillsets to be embedded at organizations working to drive forward health equity on a global scale. This year we funded and placed our first Women's Health Global Access Fellow with Calla Lily Clinical Care, in addition to two Global Access Fellows with the MAI Foundation and Med Aditus Pharmaceuticals Kenya.
Ran the Access to Medicines Internship Program, which provides real-world drug development experience to talented PharmD students who are passionate about leveraging their career development to expand healthcare access to underserved patient groups.
Partnered with Roivant to launch a two-year PharmD Post-Doctoral Fellowship in Research and Development. The inaugural fellowship was awarded to Dr.Diana Locoteta, one of the first participants in RSV's Access to Medicines PharmD Fellowship program in 2023. This fellowship aims to develop future industry leaders by accelerating their talent through placements across diverse R&D areas, such as Clinical Development; Chemistry, Manufacturing and Controls; Regulatory Affairs; Quality; Clinical Pharmacology; Program Management; Bio-Statistics; Non-clinical Development; and Translational Medicine.
Continued RSV's Convergence Forum Fellowships, which provides support for highly talented first-time female and underrepresented minority CEOs to attend an intimate, invitation only conference of prominent healthcare leaders.
Launched our Health Equity Spotlight series, which highlights organizations increasing access to research, medicine, and medical care for underserved patient groups. In 2025 we leveraged RSV's platform to spotlight the State of Women's Health Report by Springboard Enterprises, The Society for Women's Health Research, No Patient Left Behind Biotech Fellowship Program, and Women's Heath Access Matters.
Partnered with Goodlife Rwanda and Goodlife Access, to support the inaugural Genomic Frontiers Symposium in Kigali, Rwanda, which brought together researchers, clinicians, policy makers, and students to elevate genomics in Africa to the forefront of the field, reimagining the future of public health in Rwanda. As part of this partnership we sponsored six medical students to attend the symposium from countries across Africa.
Drove forward thought leadership work through speaking at and actively participating in key events to increase visibility and education on issues in healthcare access. These events included the 2025 Biotechnology Innovation Organization (BIO) CEO & Investor Conference, 2025 International Summit at the Global Observatory for Genome Editing, WHAM's Roundtable Series: The Business Case for Accelerating Women's Health, and multiple Health Equity Investing Forums.
Authored "Building Trust: A Primer on the Law, Ethics, and Importance of Increasing Patient Representation in Vaccine Clinical Trials" in the National Vaccine Law Conference's Papers and Proceedings.
As Thomas Carlyle eloquently stated, "He who has health, has hope. And he who has hope, has everything."
We look forward to connecting with all of you throughout 2026 as we continue to expand our impact!
Sincerely,
